Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGaA Keen To Remain Key Player In MS Now And In Future

Executive Summary

The German company is predicting sales in mid-triple-digits in 2019 for Mavenclad, its multiple sclerosis drug which has just been launched in the US, and has highlighted more promising MS data for its BTK inhibitor evobrutinib.

Advertisement

Related Content

F-star CEO: Revamped Merck KGaA Pact Is First Step In New Corp Direction
Keytruda/Inlyta Data Stoke Competition In Kidney Cancer
GSK Makes I-O Move With Merck KGaA Deal Worth Up To €3.7bn
Pfizer Well-Placed To Lead First-Line Advanced RCC Market
Merck KGaA Says Outcomes-Based Pact With NHS England 'Precedent-Setting'

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125217

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel